Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could ...

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior ...

Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...

Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more ...

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland.

The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.